Guideline on the clinical investigation of anti-anginal medicinal products in stable angina pectoris

We have adopted this International Scientific Guideline - CPMP/EWP/234/95/rev. 1

Last updated

17 July 2024

About this guideline

Overseas effective date: 30 November 2006

Replaces: 3CC20a (adopted by TGA 12 February 2002)

Categories: Clinical efficacy and safety | Cardiovascular system | Coronary artery disease (CAD)

TGA Annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Product types